The End of the REMS Era? Entyvio Approval Is Another Marker
This article was originally published in RPM Report
Executive Summary
FDA approved Takeda’s UC and Crohn’s disease therapy without a REMS – even though the product has a theoretical risk of causing PML, based on its similarity to Biogen’s Tysabri.